Musk’s brain implant company filed as a ‘disadvantaged business’
Elon Musk’s health tech company Neuralink labeled itself a “small disadvantaged business” in a federal filing with the U.S. Small...
Elon Musk’s health tech company Neuralink labeled itself a “small disadvantaged business” in a federal filing with the U.S. Small...
Trade tensions between the United States and the European Union have intensified, as former President Donald Trump escalates demands for...
Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration...
Talen Energy (NYSE: TLN) shares surged over 25% on Friday, reaching $330.99 in intraday trading and setting a new all-time...
Donald Trump filed a sweeping lawsuit against media magnate Rupert Murdoch, News Corp, Dow Jones, and two Wall Street Journal...
El Salvador, once hailed as the global trailblazer for national Bitcoin adoption, is quietly shifting gears. After making headlines in...
President Donald Trump said Wednesday that Coca-Cola in the United States will begin to be made with cane sugar, but...
The U.S. shipbuilding industry is looking for help. A South Korean company is answering the call. Hanwha Philly Shipyard CEO...
Global upstream merger and acquisition (M&A) activity saw a significant decline in the first half of 2025, reaching just over...
The FTSE 100 Index remained steady this month, mirroring the performance of other global indices, such as the Nasdaq 100...
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.